[ccpw id="5"]

Home.forex news reportThese 3 Stocks Rose Over 300% in 2025

These 3 Stocks Rose Over 300% in 2025

-


Green lightning bursts through stacked blocks on a desk, symbolizing a small-cap stock breakout.
Green lightning bursts through stacked blocks on a desk, symbolizing a small-cap stock breakout.
  • While small caps as a whole generated lower returns than large caps in 2025, three interesting names bucked this narrative.

  • A cancer screening company and two satellite operators saw their shares rise 300% or more.

  • See where analysts are forecasting upside and understand vital considerations pertaining to smaller stocks.

  • Interested in GRAIL, Inc.? Here are five stocks we like better.

In 2025, small-cap stocks underperformed. The Russell 2000 Index tracks the performance of 2,000 U.S. small-cap stocks, delivering a total return of around 13% in 2025. This was significantly below the S&P 500 Index’s total return of around 18%, which tracks U.S. large-cap stocks.

Despite small caps lagging behind in general, three names stood out for their exceptional performance in 2025. Below, we’ll detail three small-cap stocks that put up a return of 300% or more. This analysis will focus on stocks that started 2025 in small-cap territory. However, due to their stellar gains, they have transitioned into mid-cap stocks.

Hi Ho Silver Away! Silver Breaks $80 as Poor Man’s Gold Explodes

Healthcare stock GRAIL (NASDAQ: GRAL) rose by approximately 380% in 2025. The company’s market capitalization moved from well below $1 billion to around $3.3 billion. GRAIL’s main product is its Galleri Multi-Cancer Early Detection test.

Early detection greatly improves the chances of cancer survival, leading to significant intrigue around the product. Notably, only around five types of cancer have standardized screening methods, yet 70% of deaths come from cancers other than these five. This is why GRAIL designed Galleri to detect over 50 different types of cancer. In a recent study, GRAIL said that Galleri increased early cancer detection by more than seven times when added to traditional screening methods.

D-Wave vs. IonQ vs. IBM vs. Google: Which Quantum Bets Will Win 2026?

At this point, Galleri mostly generates sales from out-of-pocket payments. However, GRAIL expects to apply for Premarket Approval (PMA) from the U.S. Food and Drug Administration in the first quarter of 2026. If granted, this would greatly increase the likelihood of commercial insurers covering the test. This could unlock a huge new sales channel. Overall, the potential approval of Galleri is leading to significant excitement among investors.

The MarketBeat consensus price target of $97.50 indicates optimism among analysts, implying around 14% upside.

What a “Normal” Economy Could Mean for These 3 Travel Stocks



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

LATEST POSTS

Barclays Lowers PT on Brown & Brown (BRO) Stock

Brown & Brown, Inc. (NYSE:BRO) is one of the Oversold Fundamentally Strong Stocks to Buy Right Now. On January 8, Barclays analyst...

Susquehanna Lowers PT on PayPal Holdings (PYPL) Stock

PayPal Holdings, Inc. (NASDAQ:PYPL) is one of the Oversold Fundamentally Strong Stocks to Buy Right Now. On January 8, Susquehanna reduced the...

2 AI ETFs That Beat the Market in 2025. Can They Do it Again?

The Global X AI & Technology ETF gained over 37% in...

Fed’s Independence Challenged Yet Again – North American Session Market Wrap for January 12

Things will get quite busy in the next 24 hours.Today's evening session will start with a speech from the very influential NY Fed Williams...

Follow us

0FansLike
0FollowersFollow
0SubscribersSubscribe

Most Popular

spot_img